M2<scp>BPG</scp>i as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection

Wei, Bin; Feng, Shu; Chen, En‐Qiang; Li, Dongdong; Wang, Tingting; Gou, Yu Lin; Yang, Tingting; Zhang, Dongmei; Tao, Chuanmin; Tang, Hong

doi:10.1002/jcla.22261

Cited by 14 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M2BPGi levels in patients with chronic hepatitis B increase as liver fibrosis progresses. The mean M2BPGi COI values in histological fibrosis stages 1, 2, 3, and 4 are 0.26-0.9, 0.34-1.36, 0.57-1.65, and 1.21-3.1, respectively (Table 1) [52][53][54][55][56][57][58]. M2B-PGi was significantly lower in patients with chronic hepatitis B than in those with chronic hepatitis C [59].…”

Section: Utility Of M2bpgi In Chronic Hepatitis Bmentioning

confidence: 94%

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

et al. 2021

View full text Add to dashboard Cite

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review, we discuss the role of M2BPGi in diagnosing liver fibrosis in chronic hepatitis B and C, chronic hepatitis C after sustained virologic response (SVR), and nonalcoholic fatty liver disease (NAFLD). M2BPGi predicts not only liver fibrosis but also the hepatocellular carcinoma (HCC) development and prognosis in patients with chronic hepatitis B and C, chronic hepatitis C after SVR, NAFLD, and other chronic liver diseases. M2BPGi can also be used to evaluate liver function and prognosis in patients with cirrhosis. M2BPGi levels vary depending on the etiology and the presence or absence of treatment. Therefore, the threshold of M2BPGi for diagnosing liver fibrosis and predicting HCC development has to be adjusted according to the background and treatment status.

show abstract

Section: Utility Of M2bpgi In Chronic Hepatitis Bmentioning

confidence: 94%

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Zou et al 26 reported WFA+-M2BP was useful to assess early stages of liver fibrosis, and Ura et al 36 showed WFA+-M2BP was more accurate in diagnosing significant fibrosis than advanced fibrosis. In contrast, several other studies indicated that WFA+-M2BP had the strongest ability to predict cirrhosis 37,62 . In our metaanalysis, we found that the overall AUSROCs of WFA+-M2BP for identifying mild fibrosis, significant fibrosis, advanced fibrosis and cirrhosis were 0.75, 0.79, 0.82 and 0.88, respectively.…”

Section: Discussionmentioning

confidence: 74%

“…WFA+-M2BP is a serum glycobiomarker that is receiving growing attentions. It had been reported that the elevated WFA+-M2BP level was associated with the risk of HCC [57][58][59] , the loss of HBeAg in chronic hepatitis B patients 60 , and the severity of liver fibrosis 61,62 . In our meta-analysis, we evaluated 36 articles in total, and explored the predictive accuracy of WFA+-M2BP for distinguishing liver fibrosis stages and HCC by comparing with diverse non-invasive indicators.…”

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis

Feng

Wang

Zhao

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP) had been suggested as a possible glycobiomarker for assessing liver fibrosis. Here, we conducted this updated metaanalysis to systematically investigate the predictive accuracy of WFA+-M2BP for diagnosing liver fibrosis and hepatocellular carcinoma (HCC) by comparing with multiple non-invasive indicators. We searched relevant literatures from Pubmed, Web of Science, EMBASE and Cochrane Library and enrolled 36 eligible studies involving 7,362 patients. Summary results were calculated using bivariate random effects model. The pooled sensitivities, specificities and areas under the summary receiver operating characteristic curves (AUSROCs) of WFA+-M2BP for identifying mild fibrosis, significant fibrosis, advanced fibrosis, cirrhosis, and HCC were 0.

show abstract

“…M2BPGi has also been found to be useful in the assessment of fibrosis in other liver diseases. Wei et al [23] observed a positive correlation of M2BPGi with the progression of fibrosis in patients with chronic hepatitis B.…”

Section: Discussionmentioning

confidence: 98%

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection

et al. 2021

View full text Add to dashboard Cite

Oral direct-acting antiviral (DAA) treatment leads to >95% sustained virological response (SVR) and could be clinically useful in regression of liver fibrosis in chronic hepatitis C virus (HCV) infection. We evaluated if ledipasvir/sofosbuvir or sofosbuvir + ribavirin is associated with regression of fibrosis in HCV patients who achieved SVR. In this prospective cohort study performed at 3 sites in Japan, patients with genotype 1 and genotype 2 were given standard treatment of ledipasvir 90 mg/sofosbuvir 400 mg and sofosbuvir 400 mg + 200–1000 mg/day ribavirin, respectively, for 12 weeks. Liver fibrosis was assessed using Mac-2-binding protein glycosylation isomer (M2BPGi) and other fibrosis markers (platelet count, Fib-4 index, liver stiffness measurement [LSM]) in patients who achieved SVR. A total of 98.1% of (n = 101/103) patients in genotype 1 cohort and 100% (n = 16/16) in the genotype 2 cohort achieved SVR12. Based on per-protocol analysis, M2BPGi levels showed a significant decrease (–2.2 cut-off index [COI], P < .0001) at week 48 after treatment initiation. Forty-three patients showed a significant decrease in Fib-4 index (–1.2, P < .0001), and 44 patients showed improvement in LSM (–5.9 kPa, P < .0001). Achievement of SVR after antiviral therapy was associated with fibrosis regression. M2BPGi correlated well with LSM at week 48 after treatment initiation, supporting the sustainable benefit of HCV therapy.

show abstract

M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection

Abstract: M2BPGi levels increased with the progression of liver fibrosis in HBV infected patients. M2BPGi can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.

Cited by 14 publications

References 41 publications

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection

Contact Info

Product

Resources

About